OP-2024-007 Study
Active, not recruiting
- Conditions
- Parkinson's disease
- Registration Number
- jRCT2031250158
- Lead Sponsor
- OHARA Pharmaceuitical Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- Healthy Japanese male.
- BMI at time of screening is >= 18.5 to < 25.0.
- Written informed consent to participate in this trial can be obtained.
Exclusion Criteria
- History of allergies to any component of the investigational product, drug, or food.
- Subjects with or at risk for angle-closure glaucoma.
- Subjects with pheochromocytoma or paraganglioma, or other catecholamine-secreting tumors.
- History of neuroleptic malignant syndrome or nontraumatic rhabdomyolysis.
- History of diseases affecting the gastrointestinal tract, liver, kidneys, or heart that may influence the absorption, distribution, metabolism, or excretion of drugs.
- History of major surgery involving the gastrointestinal tract, including gastrectomy, gastrostomy, or bowel resection (excluding appendectomy).
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Pharmacokinetics
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of OP-2024 in modulating CYP3A4 enzyme activity in Parkinson's disease drug interactions?
How does OP-2024 compare to standard dopamine agonists in managing Parkinson's disease-related gastrointestinal symptoms?
What biomarkers are associated with drug interaction susceptibility in Parkinson's disease patients on proton pump inhibitors?
What are the potential adverse events of OP-2024 when co-administered with rabeprazole sodium in healthy volunteers?
Are there other MAO-B inhibitors being studied for Parkinson's disease that show different drug interaction profiles than OP-2024?